Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 2 , Pages 235-244 , June 2006

Endometrium in PCOS: Implantation and predisposition to endocrine CA

  • Linda C. Giudice, MD, PhD, MSc (Professor and Chair)

      Affiliations

    • Corresponding Author InformationTel.: +1 415 476 2564; fax: +1 415 476 1811.

References 

  1. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. The Journal of Clinical Endocrinology and Metabolism. 1998;83:3078–3082
  2. Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. The Journal of Clinical Endocrinology and Metabolism. 2000;85:2434–2438
  3. Balen AH, Tan SL, MacDougall J, Jacobs HS. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Human Reproduction (Oxford, England). 1993;8:959–964
  4. Okon MA, Laird SM, Tuckerman EM, Li TC. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertility and Sterility. 1998;69:682–690
  5. Fedorcsak P, Storeng R, Dale PO, Tanbo T, Abyholm T. Obesity is a risk factor for early pregnancy loss after IVF or ICSI. Acta obstetricia et Gynecologica Scandinavica. 2000;79:43–48
  6. Fedorcsak P, Dale PO, Storeng R, et al. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Human Reproduction (Oxford, England). 2001;16:1086–1091
  7. Niwa K, Imai A, Hashimoto M, et al. A case-control study of uterine endometrial cancer of pre- and post-menopausal women. Oncology Reports. 2000;7:89–93
  8. Giudice LC. Elucidating endometrial function in the post-genomic era. Human Reproduction Update. 2003;9:223–235
  9. Talbi S, Hamilton AE, Vo KC, et al. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology. 2006;147:1097–1121
  10. Gurpide E, Gusberg SB, Tseng L. Estradiol binding and metabolism in human endometrial hyperplasia and adenocarcinoma. The Journal of Steroid Biochemistry. 1976;7:891–896
  11. Falany JL, Falany CN. Regulation of estrogen sulfotransferase in human endometrial adenocarcinoma cells by progesterone. Endocrinology. 1996;137:1395–1401
  12. Slayden OD, Nayak NR, Burton KA, et al. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. The Journal of Clinical Endocrinology and Metabolism. 2001;86:2668–2679
  13. Hess A, Nayak N, Giudice LC. Cyclic changes in primate oviduct and endometrium. In:  Knobil E,  Neill JD editor. The physiology of reproduction. San Diego: Academic Press; 2005;
  14. Venturoli S, Porcu E, Fabbri R, et al. Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome. Clinical Endocrinology. 1988;28:93–107
  15. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 1991;72:83–89
  16. Robinson S, Kiddy D, Gelding SV, et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clinical Endocrinology. 1993;39:351–355
  17. Elliott JL, Hosford SL, Demopoulos RI, et al. Endometrial adenocarcinoma and polycystic ovary syndrome: risk factors, management, and prognosis. Southern Medical Journal. 2001;94:529–531
  18. Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstetrics and Gynecology. 2001;98:325–331
  19. Mertens HJ, Heineman MJ, Theunissen PH, et al. Androgen, estrogen and progesterone receptor expression in the human uterus during the menstrual cycle. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2001;98:58–65
  20. Apparao KB, Lovely LP, Gui Y, et al. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biology of Reproduction. 2002;66:297–304
  21. Tuckerman EM, Okon MA, Li T, Laird SM. Do androgens have a direct effect on endometrial function? An in vitro study. Fertility and Sterility. 2000;74:771–779
  22. Lessey BA, Damjanovich L, Coutifaris C, et al. Integrin adhesion molecules in the human endometrium. Correlation with the normal and abnormal menstrual cycle. The Journal of Clinical Investigation. 1992;90:188–195
  23. Gregory CW, Wilson EM, Apparao KBC, et al. Steroid receptor co-activator expression throughout the menstrual cycle in normal and abnormal endometrium. Journal of Clinical Endocrinology and Metabolism. 2002;87:2960–2966
  24. Lathi RB, Swiersz L, Basina M, Giudice LC. The endometrium in polycystic ovary syndrome. Current Opinion on Endocrinology Diabetes. 2002;9:480–485
  25. Giudice LC, Dsupin BA, Irwin JC. Steroid and peptide regulation of insulin-like growth factor-binding proteins secreted by human endometrial stromal cells is dependent on stromal differentiation. The Journal of Clinical Endocrinology and Metabolism. 1992;75:1235–1241
  26. Lathi RB, Hess AP, Tulac S, et al. Dose-dependent insulin regulation of insulin-like growth factor binding protein-1 in human endometrial stromal cells is mediated by distinct signaling pathways. The Journal of Clinical Endocrinology and Metabolism. 2005;90:1599–1606
  27. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews. 1997;18:774–800
  28. Nayak N, Giudice LC. Comparative biology of the IGF system in endometrium, decidua, and placenta, and clinical implications for foetal growth and implantation disorders. Placenta. 2003;24:281–296
  29. Zhou J, Dsupin BA, Giudice LC, Bondy CA. Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle. The Journal of Clinical Endocrinology and Metabolism. 1994;79:1723–1734
  30. Frost RA, Mazella J, Tseng L. Insulin-like growth factor binding protein-1 inhibits the mitogenic effect of insulin-like growth factors and progestins in human endometrial stromal cells. Biology of Reproduction. 1993;49:104–111
  31. Irwin JC, de las Fuentes L, Dsupin BA, Giudice LC. Insulin-like growth factor regulation of human endometrial stromal cell function: coordinate effects on insulin-like growth factor binding protein-1, cell proliferation and prolactin secretion. Regulatory Peptides. 1993;48:165–177
  32. Ballard FJ, Walton PE, Bastian S, et al. Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogues. Growth Regulation. 1993;3:40–44
  33. Sagle M, Bishop K, Ridley N, et al. Recurrent early miscarriage and polycystic ovaries. BMJ (Clinical research ed. ). 1988;297:1027–1028
  34. Nestler JE, Stovall D, Akhter N, et al. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertility and Sterility. 2002;77:209–215
  35. Dosiou C, Giudice LC. Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives. Endocrine Reviews. 2005;26:44–62
  36. Bolton AE, Pockley AG, Clough KJ, et al. Identification of placental protein 14 as an immunosuppressive factor in human reproduction. Lancet. 1987;1:593–595
  37. Gonzalez RR, Palomino A, Vantman D, et al. Abnormal pattern of integrin expression at the implantation window in endometrium from fertile women treated with clomiphene citrate and users of intrauterine device. Early Pregnancy. 2001;5:132–143
  38. Jakubowicz DJ, Seppala M, Jakubowicz S, et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism. 2001;86:1126–1133
  39. Ashkenazi J, Farhi J, Orvieto R, et al. Polycystic ovary syndrome patients as oocyte donors: the effect of ovarian stimulation protocol on the implantation rate of the recipient. Fertility and Sterility. 1995;64:564–567
  40. Nagamani M, Stuart CA, Dunhardt PA, Doherty MG. Specific binding sites for insulin and insulin-like growth factor I in human endometrial cancer. American Journal of Obstetrics and Gynecology. 1991;165:1865–1871
  41. Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. American Journal of Obstetrics and Gynecology. 1998;179:6–12
  42. Bermont L, Lamielle F, Lorchel F, et al. Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells. The Journal of Clinical Endocrinology and Metabolism. 2001;86:363–368
  43. Randolph JF, Kipersztok S, Ayers JW, et al. The effect of insulin on aromatase activity in isolated human endometrial glands and stroma. American Journal of Obstetrics and Gynecology. 1987;157:1534–1539
  44. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. The Proceedings of the Nutrition Society. 2001;60:91–106
  45. Roy RN, Gerulath AH, Cecutti A, Bhavnani BR. Discordant expression of insulin-like growth factors and their receptor messenger ribonucleic acids in endometrial carcinomas relative to normal endometrium. Molecular and Cellular Endocrinology. 1999;153:19–27
  46. Talavera F, Reynolds RK, Roberts JA, Menon KM. Insulin-like growth factor I receptors in normal and neoplastic human endometrium. Anticancer Research. 1990;50:3019–3024
  47. Lin J, Lei ZM, Lojun S, et al. Increased expression of luteinizing hormone/human chorionic gonadotropin receptor gene in human endometrial carcinomas. The Journal of Clinical Endocrinology and Metabolism. 1994;79:1483–1491
  48. Konishi I, Koshiyama M, Mandai M, et al. Increased expression of LH/hCG receptors in endometrial hyperplasia and carcinoma in anovulatory women. Gynecologic Oncology. 1997;65:273–280
  49. Taylor AE. Insulin-lowering medications in polycystic ovary syndrome. Obstetrics and Gynecology Clinics of North America. 2000;27:583–595

PII: S1521-690X(06)00027-3

doi: 10.1016/j.beem.2006.03.005

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 2 , Pages 235-244 , June 2006

Article Tools